sinopharm group co. ltd. - SHTDF

SHTDF

Close Chg Chg %
2.63 0.05 1.90%

Open Market

2.68

+0.05 (1.90%)

Volume: 200.00

Last Updated:

Mar 23, 2026, 11:06 AM EDT

Company Overview: sinopharm group co. ltd. - SHTDF

SHTDF Key Data

Open

$2.68

Day Range

2.68 - 2.68

52 Week Range

2.11 - 2.70

Market Cap

$8.52B

Shares Outstanding

3.12B

Public Float

1.34B

Beta

0.24

Rev. Per Employee

N/A

P/E Ratio

8.54

EPS

N/A

Yield

348.26%

Dividend

$0.10

EX-DIVIDEND DATE

Jun 23, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

110.00

 

SHTDF Performance

No Data Available

SHTDF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About sinopharm group co. ltd. - SHTDF

Sinopharm Group Co., Ltd. is a distributor of pharmaceutical and healthcare products and a value added supply chain service provider in the People's Republic of China. It operates through the following business segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment provides distribution, logistics and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers and other suppliers. The Medical Devices segment consists of the distribution of medical devices in China. The Retail Pharmacy segment refers to the network of retail drug stores in major cities of China via direct operations and franchises. The Other Business segment comprises of the production and sale of pharmaceutical products, chemical reagents and laboratory supplies. The company was founded on January 8, 2003 and is headquartered in Shanghai, China.

SHTDF At a Glance

Sinopharm Group Co., Ltd.
Sinopharm Group Building
Shanghai, Shanghai 200023
Phone 86-21-6321-1750 Revenue 80.01B
Industry Medical Distributors Net Income 995.36M
Sector Distribution Services Employees 94,910
Fiscal Year-end 12 / 2026
View SEC Filings

SHTDF Valuation

P/E Current 8.542
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 7.829
Price to Sales Ratio 0.097
Price to Book Ratio N/A
Price to Cash Flow Ratio 3.96
Enterprise Value to EBITDA 7.446
Enterprise Value to Sales 0.271
Total Debt to Enterprise Value 0.716

SHTDF Efficiency

Revenue/Employee 843,038.697
Income Per Employee 10,487.41
Receivables Turnover 2.706
Total Asset Turnover 1.459

SHTDF Liquidity

Current Ratio 1.406
Quick Ratio 1.149
Cash Ratio 0.25

SHTDF Profitability

Gross Margin 7.166
Operating Margin 2.898
Pretax Margin 2.359
Net Margin 1.244
Return on Assets 1.815
Return on Equity 8.723
Return on Total Capital 3.613
Return on Invested Capital 7.859

SHTDF Capital Structure

Total Debt to Total Equity 129.335
Total Debt to Total Capital 56.396
Total Debt to Total Assets 27.816
Long-Term Debt to Equity 7.314
Long-Term Debt to Total Capital 3.189
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Sinopharm Group Co. Ltd. - SHTDF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
82.00B 84.20B 81.22B 80.01B
Sales Growth
+1.49% +2.69% -3.54% -1.48%
Cost of Goods Sold (COGS) incl D&A
75.22B 77.61B 75.32B 74.28B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
618.53M 625.30M 657.75M 596.66M
Depreciation
560.52M 566.59M 596.36M 533.43M
Amortization of Intangibles
58.02M 58.71M 61.39M 63.23M
COGS Growth
+1.34% +3.18% -2.94% -1.39%
Gross Income
6.78B 6.59B 5.89B 5.73B
Gross Income Growth
+3.24% -2.76% -10.60% -2.71%
Gross Profit Margin
+8.27% +7.83% +7.26% +7.17%
2022 2023 2024 2025 5-year trend
SG&A Expense
3.50B 3.53B 3.49B 3.41B
Research & Development
- - - -
-
Other SG&A
3.50B 3.53B 3.49B 3.41B
SGA Growth
+2.26% +0.83% -1.04% -2.21%
Other Operating Expense
- - 26.86M 2.07M
-
Unusual Expense
3.22M (14.27M) 148.91M 66.84M
EBIT after Unusual Expense
3.25B 3.08B 2.25B 2.25B
Non Operating Income/Expense
(99.06M) (34.29M) (66.60M) (17.27M)
Non-Operating Interest Income
80.60M 104.92M 85.73M 69.59M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
554.34M 447.95M 409.24M 347.11M
Interest Expense Growth
-9.75% -19.19% -8.64% -15.18%
Gross Interest Expense
557.54M 450.78M 410.26M 348.89M
Interest Capitalized
3.20M 2.83M 1.02M 1.78M
Pretax Income
2.60B 2.60B 1.78B 1.89B
Pretax Income Growth
+5.18% -0.03% -31.53% +6.10%
Pretax Margin
+3.17% +3.09% +2.19% +2.36%
Income Tax
626.46M 635.47M 497.07M 551.61M
Income Tax - Current - Domestic
- 665.28M 656.39M 577.50M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- (38.83M) (20.92M) (80.43M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
2.13B 2.12B 1.45B 1.51B
Minority Interest Expense
864.28M 840.66M 468.81M 511.84M
Net Income
1.27B 1.28B 979.56M 995.36M
Net Income Growth
+5.25% +0.93% -23.34% +1.61%
Net Margin Growth
+1.54% +1.52% +1.21% +1.24%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.27B 1.28B 979.56M 995.36M
Preferred Dividends
- - - -
-
Net Income Available to Common
1.27B 1.28B 979.56M 995.36M
EPS (Basic)
0.4057 0.4095 0.3139 0.319
EPS (Basic) Growth
+5.24% +0.94% -23.35% +1.62%
Basic Shares Outstanding
3.12B 3.12B 3.12B 3.12B
EPS (Diluted)
0.4057 0.4095 0.3139 0.319
EPS (Diluted) Growth
+5.24% +0.94% -23.35% +1.62%
Diluted Shares Outstanding
3.12B 3.12B 3.12B 3.12B
EBITDA
3.87B 3.69B 3.06B 2.92B
EBITDA Growth
+3.12% -4.71% -17.06% -4.77%
EBITDA Margin
+4.72% +4.38% +3.77% +3.64%

Sinopharm Group Co. Ltd. in the News